Treatment with a combination of thalidomide and chemotherapy did not improve survival among patients with small cell lung cancer, and resulted in a higher risk of blood clots than treatment with chemotherapy alone. The results of this study were published in the Journal of the National Cancer Institute.
Small cell lung cancer (SCLC) accounts for approximately 15-20% of all lung cancers. Treatment of SCLC usually involves chemotherapy, but many cancers recur or progress following treatment.
Thalidomide is a drug that inhibits the development of new blood vessels. This may slow or stop cancer growth by depriving the cancer of oxygen and nutrients. Thalidomide is approved for the treatment of multiple myeloma (a cancer of plasma cells).
To evaluate thalidomide in combination with chemotherapy for the treatment of SCLC, researchers in the U.K. conducted a Phase III clinical trial among 724 patients. Roughly half had limited-stage SCLC, and half had extensive SCLC.
Cancer & COVID-19 - What You Need to Know During the "COVID" Era
What you need to know to reduce risks and receive optimal diagnosis and treatment during the COVID-19 pandemic.
COVID-19 Vaccination in Patients with Blood Cancers
Studies of COVID-19 vaccine effectiveness in myeloma and lymphoma available - vaccine relatively ineffective.
Blood Cancers and COVID-19 - What You Need to Know
COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.
All patients received chemotherapy with etoposide and carboplatin every three weeks for up to six cycles. In addition, patients were assigned to receive either thalidomide capsules or a placebo daily for up to two years.
Overall survival was 10.5 months among patients in the placebo group and 10.1 months among patients in the thalidomide group. Survival without cancer progression was also similar in the two study groups.
In analyses by disease stage, thalidomide was found to worsen overall survival among patients with extensive SCLC. Among patients with limited-stage SCLC, thalidomide did not significantly affect overall survival.
Rates of blood clots (mainly pulmonary embolus and deep vein thrombosis) were higher among patients in the thalidomide group than among patients in the placebo group. Blood clots occurred in 19% of patients in the thalidomide group compared with 10% of patients in the placebo group.
These results suggest that the addition of thalidomide to chemotherapy does not benefit—and may harm—patients with small cell lung cancer.
Reference: Lee SM, Woll PJ, Rudd R et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, double-blind, placebo-controlled trial. Journal of the National Cancer Institute. 2009;101:1049-1057.
Copyright © 2018 CancerConnect. All Rights Reserved.